Anupam Rasayan India Ltd. · NSE:ANURAS
Anupam Rasayan India — Q4 FY2022 Earnings Presentation
32 slides from Anupam Rasayan India's earnings presentation, May 12, 2022
Slide 1: Exchange filing cover letter for investor presentation
ANUPAM RASAYAN INDIALTD. ARILSLDSTX20220512012 Date: May 12, 2022 To, To, BSE Limited, Sr. General Manager Phiroze Jeejeebhoy Towers, National Stock Exchange of India Dalal Street, Limited Mumbai -400001, India “Exchange Plaza’, C-1, Block-G, SCRIP CODE: 543275 Bandra Kurla Complex Bandra (East), Mu
Slide 2: Anupam Rasayan India Limited Investor Presentation Q4FY22
ANUPAM RASAYAN INDIA LIMITED INVESTOR PRESENTATION BSE: 543275 | NSE: ANURAS | ISIN: INE930P01018 Q4FY22 ©2020 – Anupam Rasayan India Limited, All Rights Reserved. MAY 2022
Slide 3: Tables of Contents
Tables of Contents FINANCIALS AND OPERATIONAL UPDATES Slide 03 STRATEGIC PRIORITIES Slide 12 OUR BUSINESS Slide 19 TEAM Slide 28
Slide 4: Financials and Operational Updates
FINANCIALS AND OPERATIONAL UPDATES About Anupam Slide 4 Managing Director’s message Slide 5 Financials Highlights Slide 6 Last 5 Years – At a Glance Slide 9 R&D Centre Expansion Slide 11
Slide 5: About Anupam
About Anupam COMPANY AT A GLANCE Established Custom Synthesis player Specializes in multi-step Catering to globally relevant Strong supply chain with backward with 38 years of track record synthesis undertaking complex chemical & agrochemical integrated facilities chemical reactions to produce key c
Slide 6: Managing Director's Message
Managing Director’s Message Mr. Anand S Desai M A N A G I N G D I R E C TO R I am pleased to announce that we have delivered a robust year registering a total revenue growth of 29%, mostly driven by a healthy volume ramp-up. With new LOIs getting signed and older ones getting converted into long-ter
Slide 7: Annual Financial Highlights
FINANCIALS Annual Financial Highlights Operating Revenue was EBITDA (Incl. Other Revenue) was PAT stood at ₹ 1,522 Mn., ₹ 10,660 Mn ₹ 3,121 Mn.; Y-o-Y growth of 42% Y-o-Y growth of 116% PAT Margin grew by ~600 bps Acquired ~26% stake in Tanfac Commercialized new R&D Lab stood at 14% for FY22 Industr
Slide 8: Profit & Loss Summary (Full Year)
FULL YEAR FINANCIALS Profit & Loss Summary (All amounts are in ₹ Mn) FY21 FY22 INCOME Revenue from Operations 8,109 10,660 Other Income 266 151 Total Revenue 8,375 10,811 Total Revenue Growth (%) 29% EXPENSES: Cost of Raw Materials Consumed 3,390 3,699 Gross Profit 4,719 6,961 Gross Margins (%) 58%
Slide 9: Profit & Loss Summary (Quarterly)
QUARTERLY FINANCIALS Profit & Loss Summary (All amounts are in ₹ Mn) Q4FY21 Q4FY22 INCOME Revenue from Operations 2,717 3,172 Other Income 25 (4) Total Revenue 2,742 3,169 Total Revenue Growth (%) 16% EXPENSES: Cost of Raw Materials Consumed 1,213 1028 Gross Profit 1,504 2,145 Gross Margins (%) 55%
Slide 10: Last 5 Years – At a Glance
Last 5 Years – At a Glance 80 Number of Customers 60 Number of Products 70 50 10 60 5 40 50 17 40 30 6 68 48 30 58 53 53 20 20 31 25 25 10 10 0 0 FY18 FY22 FY18 FY22 Domestic Customer MNC Other Specialty Chemicals Life Science Specialty Chemicals 90 30,000 Installed Capacity R&D Strength 80 1,482 25
Slide 11: Last 5 Years – At a Glance
Last 5 Years – At a Glance ₹ 12,000 Revenue (in ₹ Mn.) 100% Gross Margin ₹ 10,000 80% • In last 5 years, Anupam has tripled its ₹ 8,000 Revenue from operations from ₹ 341 60% cr. in FY18 to ₹1,066 cr. in FY22 ₹ 6,000 40% ₹ 10,660 ₹ 4,000 ₹ 5,015 ₹ 5,289 ₹ 8,109 • Anupam has delivered consistent high
Slide 12: R&D Centre Expansion – March 2022
R&D Centre Expansion – March 2022 Added 2 new R&D Labs in existing R&D Centre in Lab Equipped with new State-of-the-art March 2022 Advance Equipment for Pharma and Agrochem Pilot Plant with 1L to 100L Capacity R&D Strength Increased to 77 in FY22 ANUPAM RASAYAN INDIA LIMITED | 11
Slide 13: Strategic Priorities
STRATEGIC PRIORITIES Fluorination: Next Phase of Growth Slide 13 Capital Expenditure Plan Slide 16
Slide 14: Fluorination Chemistry – Next Phase of Growth
Fluorination Chemistry – Next Phase of Growth Focused Segments 300 Topline Potential for Anupam ($ Mn.)* 250 Polymers 200 100 150 Pharmaceuticals 220-260 100 80-90 145 50 40-70 55 Agriculture 0 Polymer Pharma Agro Total Anupam will acquire fluorinating All molecules in these series are Targeted Seri
Slide 15: Fluorination Chemistry – Polymers Addressable Market
Fluorination Chemistry – Polymers Addressable Market Addressable market Relevant Intermediates for Addressable market Fluoropolymer is a large attractive For all the respective relevant Targeted Series Addressable Topline Potential for market with a high growth rate and Fluoropolymers Intermediates,
Slide 16: Fluorination Chemistry – Pharma Addressable Market
Fluorination Chemistry – Pharma Addressable Market ~$1T ~$1T ~$440B ~$85B ~$8B ~$3-4B ~$1T Global Pharma market Intermediate Small Market Molecule Outsourced (50% - $3- Chemistry Fluoro- 4B) (30-40%) (44%) Pharma API Market (20%) (10% - $8B) Country Technology Share of Fluoro- By API Consumption API
Slide 17: Capital Expenditure for Contracts & LOI
Capital Expenditure for Contracts & LOI EXPECTED CAPEX FOR INCREMENTAL ROCE INCREMENTAL ASSET CONTRACTS & LOI FOR THIS CAPEX TURNOVER FOR THIS CAPEX (In ₹ Mn) (In %) ( I n ti m e s ) 2,500 20% 1.75x • Signed contracts and LOI worth ₹26,200 Mn in FY22 • For this, company will incur capital expenditur
Slide 18: Strong Revenue Visibility
Strong Revenue Visibility • Signed contracts and LOI worth ₹2,620 crores in FY2022. • 6 new molecules to be commercialized in FY2023. • One LOI signed in Q4FY22, further two contracts are under final stages of signing with European multinational company. • We will be adding a new Japanese multinatio
Slide 19: Resilient Business Model
Resilient Business Model Revenue Visibility Inventory Holding Strategy Majority of Anupam’s revenue comes from long term Anupam’s products are strategic and an integral part contracts from large MNC customers. of customer’s supply chain, customer expects consistent For majority of the products under
Slide 20: Our Business
OUR BUSINESS Business Verticals and Geographies Slide 20 Key Strength: Customer Stickiness Slide 22 EHS Slide 23 Evolution of Anupam Slide 24 Strong Technical Capabilities Slide 25 Infrastructure Slide 27
Slide 21: Business Verticals
OUR BUSINESS Business Verticals BUSINESS VERTICALS OVERVIEW HISTORICAL BUSINESS PERFORMANCE Revenue from Life Science (In ₹ Mn) 91% Life Science Related Other Specialty Q4 FY 22 2,858 Specialty Chemicals Chemicals Q3 FY 22 90% 2,385 Agrochemicals FY 22 9,543 90% Specialty Pigments (including Crop Pr
Slide 22: Making a Mark Globally
OUR BUSINESS Making a Mark Globally MANUFACTURING CLIENTELE UNITS IN INDIA GLOBALLY (In Nos.) (In Nos.) 6* 68* REVENUE BY GEOGRAPHY EUROPE 26% EUROPE 28% INDIA 44% INDIA 42% SINGAPORE 11% SINGAPORE 10% FY21 FY22 JAPAN 12% JAPAN 15% CHINA 4% CHINA 4% NORTH 1% REST OF 1% AMERICA WORLD REST OF 1% WORLD
Slide 23: Key Strength: Customer Stickiness
OUR BUSINESS Key Strength: Customer Stickiness FEW OF OUR TOP GLOBAL CLIENTS • Long-standing relationships, clients onboarded after significant gestation period • Stringent customer audits, approvals & requirements adhered too • Dealing with top MNCs around the globe supplying them niche molecules •
Slide 24: EHS at Anupam Rasayan
OUR BUSINESS EHS at Anupam Rasayan WASTE MANAGEMENT ENVIRONMENT MANAGEMENT SAFETY COMMITED TO MAKE POSITIVE IMPACT WE BELIEVE PROTECTING THE WELL BEING COMMITTED TO CONDUCTING ALL OUR ON THE ENVIRONMENT OF OUR EMPLOYEE AND ENVIRONMENT IS OPERATION IN SAFE AND RELIABLE OUR RESPONSIBILITY MANNER • Zer
Slide 25: Evolution of Anupam
OUR BUSINESS Evolution of Anupam Company was formed as a Started supplying specialty Awarded ‘Green Innovation Commercialized Unit – 5 in • Started working with partnership firm as “Anupam chemicals to Syngenta Award’ by Corning Reactor Jhagadia GIDC and Unit – 6 Adama Rasayan” Technology in Sachin
Slide 26: Strong Technical Capabilities
OUR BUSINESS Strong Technical Capabilities COMPETENCE IN KEY CHEMISTRIES DSIR recognized R&D center R&D headed by Dr. Nileshkumar Naik, with team of 77 professionals Etherification Chlorination Diazotization & hydrolysis R&D team oversees transfer of Received the ‘Corning Green technology from lab s
Slide 27: Strong Technical Capabilities (Contd.)
OUR BUSINESS Strong Technical Capabilities (Contd.) PROCESS TECHNOLOGIES DEPLOYED Flow Chemistry Photo Chemistry Significant advantages of flow chemistry technology over traditional Increasingly becoming an important tool in the search of new active batch process : compounds for specialty chemicals
Slide 28: World-class Infrastructure
OUR BUSINESS World-class Infrastructure • Manufacturing operations were commenced in 1984 HIGHLIGHTS • Highly automated multi-purpose facilities • Equipped with glass-lined, titanium cladded and stainless-steel reactors enabling manufacture of diverse range of products • Strategically located close
Slide 29: Team
TEAM Team of Anupam Slide 29
Slide 30: Board of Directors
TEAM Board of Directors DR. KIRAN C PATEL MR. ANAND S DESAI MS. MONA A DESAI MR. MILAN THAKKAR CHAIRMAN & MANAGING DIRECTOR VICE-CHAIRMAN & NON-EXECUTIVE DIRECTOR NON-EXECUTIVE DIRECTOR WHOLE-TIME DIRECTOR • Associated with the company for past • Over 30 years of experience in • Over 20 years of exp
Slide 31: Safe Harbor
Safe Harbor Safe Harbor Certain statements in this presentation concerning our future growth prospects are forward looking statements, which involve a number of risks, and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The company's
Slide 32: Thank You
THANK YOU CONTACT US: MR. VISHAL THAKKAR MR. RAVISH CHAUDHARY Anupam Rasayan India Ltd. investors@anupamrasayan.com MR. KANAV KHANNA MR. DIWAKAR PINGLE EY Investor Relations kanav.khanna@in.ey.com diwakar.pingle@ey.com CORPORATE OFFICE Anupam Rasayan India Ltd. India (HQ) 8110, Sachin G.I.D.C. Estat
Anupam Rasayan India — Q4 FY2022 Earnings Presentation on 6ix